AC-101

AC-201, an oral selective TYK2/JAK1 inhibitor, met its primary endpoint with up to 74.3% of patients achieving PASI-75 responses at week 12 across all three dosing regimens tested.

The FDA has granted orphan drug designation to HLX22, a novel anti-HER2 monoclonal antibody that targets HER2 extracellular subdomain IV, for the treatment of gastric cancer.

Accropeutics has closed a $12 million Series B+ financing round led by Shenzhen Capital Group, with participation from existing and new investors, extending its cash runway into the second half of 2026.

DelveInsight's comprehensive analysis reveals over 200 companies actively developing 220+ pipeline therapies for gastric cancer treatment, indicating significant industry investment in addressing this disease.

Alligator Bioscience completed an End-of-Phase 2 interaction with the FDA, receiving positive feedback on its clinical development strategy for mitazalimab.